GlassScriptPhysician profile
Eugene M Spear
NPI 1891787685
$1,127.71
in general payments reported to CMS, 2019-2025
15 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $77.44 · 2021: $29.84 · 2022: $148 · 2023: $288 · 2024: $47.34 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $362 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $362.41 |
| Education | $109.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $267.17 | 2019-2025 | Aveir, Jot Dx |
| Actelion Pharmaceuticals US, INC. | $206.80 | 2019-2024 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $168.21 | 2022-2023 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $146.00 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $64.82 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.01 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $50.76 | 2019 | |
| Amgen INC. | $45.46 | 2019 | |
| Lundbeck LLC | $24.02 | 2019 | |
| Chiesi USA, INC. | $22.88 | 2023 | Kengreal, Cleviprex |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.03 | 2019 | |
| Lantheus Medical Imaging, INC. | $15.07 | 2020 | |
| Becton, Dickinson and Company | $14.50 | 2019 | |
| Cordis US Corp. | $11.84 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Spear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.